ClinicalTrials.gg
Status unknownNCT05790382Updated Mar 30, 2023

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

A Phase 1 interventional study of NM-101 and Placebo in Parkinson Disease, sponsored by Neuramedy Co. Ltd.. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-30.

Sponsored by Neuramedy Co. Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.

Planned enrollment
114th of 183
56 · median 80
Started
2023
with 19 others
Phase 1
26 of 246
2 open now
Registered
189th of 246
by date

Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 114th largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2023, is one of 26 in phase 1, and was the 189th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Parkinson Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and multiple-ascending dose (Part 2) study of NM-101 in healthy males and healthy females of non-childbearing potential

Read the detailed description

NM-101 is an anti-TLR2 antibody which may have clinical efficacy in Parkinson's disease patients. This Phase I study aims to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of NM-101 in healthy males and healthy females of non-childbearing potential. A total of 56 subjects (8 per cohort) are planned to be enrolled.

Subjects will be randomly assigned to recieve NM-101 or placebo in a 3:1 ratio. The study will be in 2 parts: Part 1 will consist of 3 single-dose cohorts; Part 2 will consist of 4 multiple-dose cohorts.

In Part 1, sentinel dosing will be applied. In each cohort, 1 subject will be randomised to receive NM-101 and 1 subject will be randomised to receive placebo ahead of dosing in the remaining 6 subjects. The dose for Cohort 1 is 20 mg/kg NN-101. The predicted doses for Cohorts 2 and 3 are 40 mg/kg and 60 mg/kg NM-101, respectively (dependent on a blinded interim review of the safety, tolerability and PK data). Blood samples will be collected at regular intervals for PK analysis and safety from Day 1 until Day 42.

In Part 2, sentinel dosing will not be applied. Each subject will receive 4 doses of NM-101 or placebo over the course of 3 months. Dosing may occur in parallel to the conduct of Part 1. The doses administered will be selected based on emerging safety, tolerability and PK data from preceding groups in Part 1. The predicted NM-101 doses are: 10 mg/kg for Cohort 4; 20 mg/kg for Cohort 5; 40 mg/kg for Cohort 6; 60 mg/kg for Cohort 7. In Cohorts 5 to 7, subjects will undergo a lumbar puncture to assess NM-101 concentrations in the cerebrospinal fluid. Blood samples will be collected at regular intervals for PK analysis and safety from Day 1 until Day 127.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • NM-101
  • Anti-TLR2 antibody
  • Blood-brain barrier
  • Ascending dose
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

and Compliance

  1. Must provide written informed consent
  2. Must be willing and able to communicate and participate in the whole study

    Demographics and

  3. Aged 18 to 65 years inclusive at the time of signing informed consent
  4. Must agree to adhere to the contraception requirements

    Baseline Characteristics

  5. Healthy males or WONCBP
  6. (BMI) of 18.0 to 32.0 kg/m2 as measured at screening

    Other

  7. Must have received at least 2 doses of a COVID-19 vaccine

Exclusion criteria

Exclusion Criteria:

Medical/Surgical History and Mental Health

  1. Serious adverse reaction or serious to any drug or formulation
  2. History of allergic or anaphylactic reactions to humanised or other therapeutic monoclonal antibodies or to any of the excipients of NM-101
  3. Presence or history of allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
  4. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
  5. Undergone a lumbar puncture within 6 weeks before Day 1 (Part 2 only)
  6. Medical history or evidence of mass occupying lesion in brain or spinal cord or history of spinal cord injury, which could preclude the procedure of lumbar puncture and CSF collection (Part 2 only)
  7. Evidence or history of clinically significant back pain, back pathology and/or back injury (e.g. degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulties in the conduct of a lumbar puncture (Part 2 only)

    Physical Examination

  8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening

    Diagnostic Assessments

  9. Evidence of current SARS-CoV-2 infection
  10. History of an infection requiring treatment within 14 days of first dose of the IMP
  11. A history of any ongoing, chronic or recurrent infectious disease, herpes, or evidence of tuberculosis infection as defined by a positive QuantiFERON® TB Gold test at screening
  12. Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator
  13. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) 1 and 2 antibody results
  14. Females of including those who are pregnant or lactating (all female subjects must have a negative highly sensitive serum pregnancy test)

    Prior Study Participation

  15. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
  16. Subjects who have previously been administered IMP in this study. Subjects who have taken part in Part 1 are not permitted to take part in Part 2 and vice versa
  17. Subjects who report to have previously received NM-101 (formerly known as OPN-305)
  18. Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood

    Prior and Concomitant Medication

  19. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day or HRT) in the 14 days before first IMP administration. Exceptions may apply, as determined by the investigator
  20. Subjects who have had a vaccine (including COVID-19 vaccine) within 28 days before first dose
  21. Have taken non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or function within 14 days prior to scheduled lumbar puncture (Part 2 only)

    Lifestyle Characteristics

  22. History of any drug or alcohol abuse in the past 2 years
  23. Regular alcohol consumption in males >21 units per week and in females >14 units per week
  24. A confirmed positive alcohol breath test at screening or admission
  25. Current smokers and those who have smoked within the last 12 months
  26. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
  27. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  28. Confirmed positive drugs of abuse test result

    Other

  29. Male subjects with pregnant or lactating partners
  30. Travelled to an area where there is risk of malaria within the past year unless adequate precautions were taken
  31. Subjects who are, or are immediate family members of, a study site or sponsor employee
  32. Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    NM-101

    Ascending doses of NM-101. IV infusion over 2 hours

    Drug: NM-101

  • Placebo comparator
    Placebo

    IV infusion over 2 hours

    Drug: Placebo

Interventions

  • DrugNM-101

    In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts). In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts).

    Also known as: Tomarilimab, OPN-305 (formerly)

  • DrugPlacebo

    Placebo solution for infusion

06

What researchers measure

Primary outcomes

  1. Safety of NM-101: Incidence of Treatment-Related Adverse Events by Severity

    A treatment related adverse event is defined as a clinical event with plausible time relationship to NM-101 administration and that cannot be explained by concurrent disease or other drugs or chemicals

    Time frame: up to 4 months

  2. PK Parameter

    maximum concentration (Cmax)

    Time frame: up to 4 months

  3. PK Parameter

    time of the maximum measured concentration (Tmax)

    Time frame: up to 4 months

  4. PK Parameter

    area under the concentration-time curve from time (AUC)

    Time frame: up to 4 months

  5. PK Parameter

    First order rate constant associated with the terminal portion of the curve (Lambda-z)

    Time frame: up to 4 months

  6. PK Parameter

    terminal elimination half life (t1/2)

    Time frame: up to 4 months

  7. PK Parameter

    clearance (CL)

    Time frame: up to 4 months

  8. PK Parameter

    Volume of distribution based on the terminal phase (Vz)

    Time frame: up to 4 months

  9. PK Parameter

    Volume of distribution at steady state (Vss)

    Time frame: up to 4 months

Secondary outcomes

  1. Cerebrospinal Fluid (CSF) Concentrations of NM-101

    Quantification of NM-101 24 h after the dose only in Cohorts 5 to 7

    Time frame: Day 2 or Day 86

  2. Immunogenicity of NM-101

    Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101 Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101 Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101

    Time frame: up to 4 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for May 2024, 12 months later.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 12 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 30, 2023
StartEst.
May 10, 2023
Primary completionEst.
May 30, 2024
CompletionEst.
Jun 14, 2024
Last update
Mar 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05790382
Lead sponsor
Neuramedy Co. Ltd.
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
May 10, 2023 (estimated)
Primary completion
May 30, 2024 (estimated)
Completion
Jun 14, 2024 (estimated)
Last update
Mar 30, 2023

Study contacts

Stuart Mair, MBChB, etc.
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion